Celldex Therapeutics, Inc. — News

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

zacks.com - 2026-07-24 10:41:20

Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony Marucci, Celldex's co-founder, president and chief executive officer, said the company was

defenseworld.net - 2026-07-24 01:02:37

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript

seekingalpha.com - 2026-07-22 13:10:52

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday said it is ending its Phase 2 clinical trial evaluating barzolvolimab for prurigo nodularis, a chronic condition characterized by intensely itchy skin nodules.

benzinga.com - 2026-07-22 07:29:53

Celldex Therapeutics NASDAQ: CLDX said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies.

marketbeat.com - 2026-07-22 06:03:06

Celldex Therapeutics said on Tuesday it would discontinue the ​development of its experimental drug for a skin disease ‌after it failed to meet the main goal and key secondary goals in a mid-stage study, sending its shares down over 7% in ​extended trading.

reuters.com - 2026-07-21 16:44:36

HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The primary endpoint of the study, the proportion of patients who achieve a four point or greater improvement in WI-NRS (Worst Itch Numeric Rating Scale) from baseline to Week 12, and key secondary endpoints were not met.

globenewswire.com - 2026-07-21 16:01:00

HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company's Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as the Company's CFO through March of 2027, to support a smooth transition.

globenewswire.com - 2026-07-15 16:01:00

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab's potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

globenewswire.com - 2026-06-14 10:21:00

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levels. Building on Celldex's leadership in mast cell science, the data also demonstrated that neutralizing soluble stem cell factor (SCF) enables the potential for meaningful mast cell inhibition and depletion without impacting other KIT-dependent functions. CDX-622 is currently being studied in a Phase 1b proof of mechanism study in mild to moderate asthma to assess the impact of dual neutralization of SCF and TSLP.

globenewswire.com - 2026-06-14 05:15:00

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026.

globenewswire.com - 2026-06-10 16:01:00

-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria ---- Late-breaking poster presentation on CDX-622 -- HAMPTON, N. J. , June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026.

globenewswire.com - 2026-06-10 16:01:00

Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago.

zacks.com - 2026-05-07 18:55:22

HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

globenewswire.com - 2026-05-07 16:01:00

Celldex is positioned as a platform immunology company, leveraging barzolvolimab's mast-cell depletion mechanism beyond chronic urticaria. CLDX's robust cash position ($518.6M at 2025 year-end, $345M raised in April 2026) supports operations through 2027, mitigating near-term dilution risk. Phase 3 enrollment for CSU completed six months early; top-line data expected Q4/26, with BLA filing planned for 2027.

seekingalpha.com - 2026-05-07 08:55:54

The mean of analysts' price targets for Celldex (CLDX) points to a 76.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-05-04 10:56:05